灯盏生脉胶囊联合瑞舒伐他汀钙治疗 冠心病合并高脂血症临床研究

Clinical Researoh of Dengzhan Shengmai Capsule Combined with Rosuvastatin Calcium in the Treatment of Coronary Heart Disease Complicated with Hyperlipidemia

摘要:

〔摘 要〕 目的：分析研究灯盏生脉胶囊与瑞舒伐他汀钙联合应用对于冠心病合并高脂血症的临床治疗效果。 方法：回顾性选取中山大学附属第三医院粤东医院于 2021 年 1 月至 2023 年 1 月收治的 90 例冠心病合并高脂血症患者的临床相关 资料，并根据两种不同的治疗方案将患者分为观察组和对照组，各 45 例。两组均进行心理干预、饮食指导等临床常规干预 措施，于此基础上对照组采用瑞舒伐他汀钙进行治疗，观察组在对照组基础上增加灯盏生脉胶囊口服治疗。比较两组患者 治疗效果、不良反应发生情况以及治疗前后血脂指标、心功能指标。 结果：观察组患者治疗总有效率高于对照组，差异具 有统计学意义（P ＜ 0.05）。治疗后，观察组患者血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL–C） 水平低于对照组，差异具有统计学意义（P ＜ 0.05）。治疗后，观察组患者左心室舒张末期内径（LVEDD）、左心室收缩 末期内径（LVESD）低于对照组，左心室射血分数（LVEF）高于对照组，差异具有统计学意义（P ＜ 0.05）。两组患者不 良反应发生率比较，差异无统计学意义（P ＞ 0.05）。 结论：灯盏生脉胶囊与瑞舒伐他汀钙联合应用对于冠心病合并高脂 血症的临床治疗效果较高，可有效改善患者的血脂和心功能水平。

Abstract:

〔Abstract〕 Objective To analyze the clinical effect of Dengzhan Shengmai capsule combined with rosuvastatin calcium in the treatment of coronary heart disease complicated with hyperlipidemia. Methods Clinical data of 90 patients with coronary heart disease combined with hyperlipidemia admitted to the Third Affiliated Hospital of Sun Yat-Sen University-Yuedong from January 2021 to January 2023 were retrospectively selected, and the patients were divided into an observation group and a control group according to two different treatment schemes, with 45 cases in each group. Both groups received routine clinical intervention measures such as psychological intervention and dietary guidance. On the basis of this, the control group was treated with rosuvastatin calcium, and the observation group was additionally treated with Dengzhan Shengmai capsule orally. The treatment effect, occurrence of adverse reactions, blood lipid index and cardiac function index before and after treatment were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P < 0.05). After treatment, the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). After treatment, left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) in the observation group were lower than those in the control group, and left ventricular ejection fraction (LVEF) was higher than that in the control group, with statistical significance (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Dengzhan Shengmai capsule combined with rosuvastatin calcium has a high clinical effect on coronary heart disease complicated with hyperlipidemia, which can effectively improve the blood lipid level and cardiac function of patients, and has certain application value.